Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial
一项随机、多中心、安慰剂对照的3期临床试验结果显示,新型血小板生成素受体激动剂海曲波帕治疗儿童和青少年免疫性血小板减少症的疗效和安全性
期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-026-01790-x
Wu, Runhui; Gao, Ju; Liu, Yufeng; Yu, Jie; Hu, Shaoyan; Liang, Hui; Jiang, Hui; Zhai, Xiaowen; Zhou, Min; Hao, Wenge; Mei, Heng; Li, Fei; Chen, Yumei; Liu, Wei; Yan, Mei; Li, Runzi; Xiong, Junye; Zhu, Zhenyi; Cheng, Xiaoling; Wang, Tianyou